A novel approach for first‐in‐human dose selection using population dose–response modelling to find a minimum anticipated biological effect level

20251 citationsJournal Article

Authors

Lin Yuan

Meghana Kulkarni · Silicon Therapeutics (United States)

Evan L. Chiswick · Silicon Therapeutics (United States)

Cheryl M. Koh · Silicon Therapeutics (United States)

Péter Sandy · Silicon Therapeutics (United States)

Salah Nabhan · Silicon Therapeutics (United States)

Woody Sherman · Silicon Therapeutics (United States)

Abstract

Our novel population modelling-based MABEL strategy for first-in-human dose selection resulted in successful clinical translation of a small molecule STING agonist.

Topics & Keywords

interferon and immune responses Influenza Virus Research Studies Immune Response and Inflammation

Publication Details

Published in: British Journal of Clinical Pharmacology

Volume 91, Issue 9, pp. 2555-2566

DOI: 10.1002/bcp.70067

Field-Weighted Citation Impact: 0.89

Command Palette

A novel approach for first‐in‐human dose selection using population dose–response modelling to find a minimum anticipated biological effect level

Authors

Abstract

Topics & Keywords

Publication Details